FDA Ruling On Gepirone Efficacy Data Delayed By One Month
This article was originally published in The Pink Sheet Daily
Executive Summary
Fabre-Kramer responds to Office of New Drugs Director Jenkins' invitation to submit additional information following advisory committee review; Jenkins' decision on the antidepressant now expected by end of January.